Evidence map›Paper›PMID 32780006›Full record

ArticleRadiology2020

NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation.

Etay Ziv, Yiru Zhang, Luke Kelly, Ines Nikolovski, F Edward Boas, Joseph P Erinjeri, Liqun Cai, Elena N Petre, Lynn A Brody, Anne M Covey and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Etay ZivFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).ORCID 0000-0002-3188-0085
Yiru ZhangFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).
Luke KellyFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).ORCID 0000-0002-6331-7334
Ines NikolovskiFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).
F Edward BoasFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).ORCID 0000-0002-1382-5365
Joseph P ErinjeriFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).ORCID 0000-0003-1876-727X
Liqun CaiFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).
Elena N PetreFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).
Lynn A BrodyFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).ORCID 0000-0002-9786-3085
Anne M CoveyFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).ORCID 0000-0002-1477-8468
George GetrajdmanFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).
James J HardingFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).
Constantinos SofocleousFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).ORCID 0000-0002-3142-1399
Ghassan K Abou-AlfaFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).ORCID 0000-0002-1522-8054
Stephen B SolomonFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).ORCID 0000-0001-5108-1021
Karen T BrownFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).ORCID 0000-0003-2434-0037
Hooman YarmohammadiFrom the Department of Radiology (E.Z., L.K., I.N., F.E.B., J.P.E., L.C., E.N.P., L.A.B., A.M.C., G.G., C.S., S.B.S., H.Y.), Sloan Kettering Institute (Y.Z.), and Department of Medicine (J.J.H., G.K.A.), Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Department of Radiology, University of Utah Health, Salt Lake City, Utah (K.T.B.); and Weill Medical College at Cornell University, New York, NY (E.Z., I.N., F.E.B., J.P.E., A.M.C., G.G., J.J.H., C.S., G.K.A., S.G.S., H.Y.).
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background Intermediate stage hepatocellular carcinomas (HCCs) are treated by inducing ischemic cell death with transarterial embolization (TAE) or transarterial chemoembolization (TACE). A subset of HCCs harbor nuclear factor E2-related factor 2 (NRF2), a major regulator of the oxidative stress response implicated in cell survival after ischemia. NRF2-mutated HCC response to TAE and/or TACE is unknown. Purpose To test whether ischemia resistance is present in individuals with NRF2-mutated HCC and if this resistance can be overcome by means of NRF2 inhibition in HCC cell lines. Materials and Methods This was a combined retrospective review of an institutional database (from January 2011 to December 2018) and prospective study (from January 2014 to December 2018) of participants with HCC who underwent TAE and a laboratory investigation of HCC cell lines. Imaging follow-up included liver CT or MRI at 1 month after the procedure followed by 3-month interval scans. Tumor radiologic response was assessed on the basis of follow-up imaging. The time to local progression after TAE for individuals with and individuals without NRF2 pathway alterations was estimated by using competing risk analysis (Gray test). The in vitro response to ischemia in four HCC cell lines with and without NRF2 overexpression was evaluated, and the combination of ischemia with NRF2 knockdown by means of short hairpin RNA or an NRF2 inhibitor was tested. Doubling time estimates, dose response curve regression, and comparison analyses were performed. Results Sixty-five individuals (median age, 69 years [range, 19-84 years]; 53 men) were evaluated. HCCs with NRF2 pathway mutation had a shorter time to local progression after TAE compared to those without mutation (6-month cumulative incidence of local progression, 56% [range, 19%-91%] vs 22% [range, 12%-34%], respectively;

Indexed as

AdultAgedAged, 80 and overCarcinoma, HepatocellularCell Line, TumorDisease ProgressionEmbolization, TherapeuticFemaleHumansIschemiaLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedMutationNF-E2-Related Factor 2NF-E2-Related Factor 2

Identifiers

PMID32780006
PMCPMC7526944
OpenAlexW3048530407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.